ZX008 (Fenfluramine Hydrochloride)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
Trial Timeline
Apr 22, 2019 → May 8, 2025
NCT ID
NCT03936777About ZX008 (Fenfluramine Hydrochloride)
ZX008 (Fenfluramine Hydrochloride) is a phase 3 stage product being developed by UCB for Dravet Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03936777. Target conditions include Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03936777 | Phase 3 | Completed |
| NCT03299842 | Phase 3 | Terminated |
| NCT02823145 | Phase 3 | Completed |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 30 |
| fenfluramine | UCB | Approved | 82 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 20 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| fenfluramine | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 82 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 72 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 36 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 47 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |